Amy L. Burroughs, Chief Executive Officer at Terns Pharmaceuticals, Inc. (TERN), sold 29,166 shares at $46.57 ($1.4M) on 2026-03-16, disclosed to the SEC on 2026-03-17.
Scheduled sale ($1.4M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $46.57 | 11,813 | $550K | 40.4% |
| 2 | $46.57 | 11,813 | $550K | 40.4% |
| 3 | $47.30 | 2,770 | $131K | 9.6% |
| 4 | $47.30 | 2,770 | $131K | 9.6% |
| Total | $46.71 avg | 29,166 | $1.4M | 100% |
| Filing → |
| TERN | SELL | 2026-01-06 | $5.4M | — | Filing → |
| TERN | BUY | 2025-06-25 | $180K | — | Filing → |
| TERN | BUY | 2025-02-03 | $3K | — | Filing → |